ジェノタイピングアッセイの世界市場予測(~2023年)

◆英語タイトル:Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023
◆商品コード:BT-3397
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2018年11月21日
◆ページ数:281
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

ジェノタイピングアッセイの世界市場は、2018年の推定118億米ドルから2023年には319億米ドルに達し、22.0%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、技術の進歩、DNAシーケンシングの価格の低下、および遺伝性疾患の増加が考えれられます。一方で、機器のコストが高いことにより、市場の成長が抑制される可能性があります。当調査レポートでは、ジェノタイピングアッセイの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、技術(PCR、シークエンシング、マイクロアレイ、電気泳動、MALDI-TOF)分析、用途(薬理ゲノミクス、診断研究、動物遺伝学、農業バイオテクノロジー)分析、製品分析、ジェノタイピングアッセイの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

“The global genotyping market is projected to grow at a CAGR of 22.0%.”The genotyping market is expected to reach USD 31.9 billion by 2023 from an estimated USD 11.8 billion in 2018, at a CAGR of 22.0%. Technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases are expected to drive the growth of the global genotyping market. However, the high cost of equipment is expected to restrain market growth to a certain extent during the forecast period.

“Pharmacogenomics application segment to witness the highest growth during the forecast period.”
On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostic & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to register the highest CAGR during the forecast period. The increased use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs are the major factors driving the growth of this market segment.

“Pharmaceutical and biopharmaceutical companies end-user segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of end user, the genotyping market is segmented into pharmaceutical & biopharmaceutical companies, diagnostic & research institutes, academic institutes, and other end users. The pharmaceutical & biopharmaceutical companies segment is expected to witness the highest CAGR owing to the growing importance of biomarkers in genotyping used among these end users, given their applications in drug development which, in turn, will support the growth of this segment.

“APAC is projected to witness the highest growth during the forecast period.”
North America is expected to account for the largest share of the global genotyping market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing incidence of chronic diseases and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases & the spread of infectious and microbial diseases in APAC countries. The increasing outsourcing of clinical research and trials by pharmaceutical and biopharmaceutical companies to organizations in the APAC has driven the demand for genotyping products for drug profile assessment, drug efficacy, safety assessment, dosing determination, and drug response evaluation.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–46%, Tier 2–33%, and Tier 3–21%
• By Designation: C-level–43%, Director Level–35%, and Others–22%
• By Region: North America–34%, Europe–26%, Asia Pacific–19%, Latin America–11%, and the Middle East & Africa–10%

The prominent players in the global genotyping market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
Research Coverage:
The report analyzes the market for various genotyping products and their adoption pattern. It aims at estimating the market size and future growth potential of the global genotyping market and different segments such as products, technology, applications, end users, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global genotyping market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global genotyping market
• Market Development: Comprehensive information on the lucrative emerging regions by product, technology, application, end user, and region
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global genotyping market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global genotyping market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 MARKET SEGMENTATION, BY REGION 24
1.3.3 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.1.1 SECONDARY DATA 27
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY DATA 28
2.1.2.1 Key data from primary sources 30
2.1.2.2 Key industry insights 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 BOTTOM-UP APPROACH 33
2.2.2 TOP-DOWN APPROACH 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.4 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 44
4.1 GENOTYPING MARKET OVERVIEW 44
4.2 ASIA PACIFIC: GENOTYPING MARKET, BY PRODUCT & SERVICE, BY COUNTRY, 2017 45
4.3 GEOGRAPHIC SNAPSHOT OF THE GENOTYPING MARKET 46
4.4 GEOGRAPHIC MIX: GENOTYPING MARKET 47
4.5 GENOTYPING MARKET: DEVELOPING VS. DEVELOPED MARKETS 47

5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 48
5.3 MARKET DRIVERS 49
5.3.1 TECHNOLOGICAL ADVANCEMENTS AND DECREASING PRICES OF DNA SEQUENCING 49
5.3.2 INCREASING INCIDENCE OF GENETIC DISEASES AND RISING AWARENESS ON PERSONALIZED MEDICINE 50
5.3.3 GROWING IMPORTANCE OF GENOTYPING IN DRUG DEVELOPMENT 51
5.3.4 INCREASING DEMAND FOR BIOINFORMATICS SOLUTIONS IN DATA ANALYSIS 51
5.4 MARKET RESTRAINTS 52
5.4.1 HIGH COST OF EQUIPMENT USED IN GENOTYPING 52
5.5 MARKET OPPORTUNITIES 52
5.5.1 GROWING IMPORTANCE OF SEQUENCING PROJECTS 52
5.5.2 INCREASING APPLICATION AREAS OF GENOTYPING 53
5.5.3 INCREASING DEMAND FOR GENOME ANALYSIS IN PLANT AND ANIMAL LIVESTOCK 53
5.6 MARKET CHALLENGES 54
5.6.1 DATA MANAGEMENT IN GENOTYPING RESEARCH 54
5.6.2 DEARTH OF TRAINED RESOURCES 54
6 INDUSTRY INSIGHTS 55
6.1 INDUSTRY TRENDS 55
6.1.1 INCREASING DEMAND FOR GENOTYPING & SEQUENCING SERVICES 55
6.1.2 INCREASING COLLABORATIONS 55
6.1.3 INCREASING AWARENESS 56
6.2 REGULATORY ANALYSIS 57
6.2.1 US 57
6.2.2 EUROPE 58
6.2.3 JAPAN 58
6.2.4 CHINA 59
6.2.5 INDIA 60
6.3 STRATEGIC BENCHMARKING 61
6.3.1 GENOTYPING MARKET: PRODUCT PORTFOLIO ANALYSIS (INSTRUMENTS & KITS) 61
6.3.2 GENOTYPING MARKET: PRODUCT PORTFOLIO ANALYSIS (BIOINFORMATICS) 62

7 GENOTYPING MARKET, BY PRODUCT & SERVICE 63
7.1 INTRODUCTION 64
7.2 REAGENTS & KITS 65
7.2.1 REAGENTS & KITS ACCOUNTED FOR THE LARGEST SHARE OF THE GENOTYPING MARKET IN 2017 65
7.3 GENOTYPING SERVICES 66
7.3.1 INCREASING DEMAND FOR SEQUENCING AND GENOTYPING SERVICES FROM HOSPITALS, SMALL- AND MEDIUM-SIZED RESEARCH CENTERS, AND PHARMACEUTICAL COMPANIES TO DRIVE THE GROWTH OF THIS SEGMENT 66
7.4 INSTRUMENTS 67
7.4.1 SEQUENCERS & AMPLIFIERS 69
7.4.1.1 Sequencers & amplifiers segment to register the highest growth rate in the genotyping instruments market during the forecast period 69
7.4.2 ANALYZERS 70
7.4.2.1 Growing automation and advancements in analyzers with high-throughput capacities are the major factors driving market growth 70
7.5 BIOINFORMATICS 71
7.5.1 SOFTWARE 73
7.5.1.1 Software segment accounted for the largest share of the genotyping bioinformatics market in 2017 73
7.5.2 SERVICES 74
7.5.2.1 Shortage of skilled bioinformatics professionals and the growing applications of bioinformatics in various industries are the major factors driving the growth of this segment 74
8 GENOTYPING MARKET, BY TECHNOLOGY 76
8.1 INTRODUCTION 77
8.2 POLYMERASE CHAIN REACTION 78
8.2.1 REAL-TIME PCR 80
8.2.1.1 Real-time PCR dominated the PCR market in 2017, primarily due to the growing adoption of these instruments among researchers and healthcare professionals 80
8.2.2 DIGITAL PCR 83
8.2.2.1 The high cost of dPCR instruments to restrain the growth of this market 83
8.3 MICROARRAYS 85
8.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE AND CONTINUOUS LAUNCH OF CUSTOM ARRAYS BY LEADING PLAYERS TO DRIVE MARKET GROWTH 85
8.4 SEQUENCING 88
8.4.1 NEXT-GENERATION SEQUENCING 90
8.4.1.1 NGS to witness the highest growth rate in the sequencing market during the forecast period 90

8.4.2 PYROSEQUENCING 92
8.4.2.1 Growing demand for pyrosequencing by pharmaceutical and biotechnology companies to drive the adoption of this technology segment 92
8.4.3 SANGER SEQUENCING 94
8.4.3.1 Increasing use of this technology in small-scale experiments is the major factor driving market growth 94
8.5 CAPILLARY ELECTROPHORESIS 96
8.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM 98
8.5.1.1 AFLP technique to witness the highest growth rate in the capillary electrophoresis market during the forecast period 98
8.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM 99
8.5.2.1 Increasing demand for RFLP from forensics, agricultural institutions, and pharmaceutical and biotechnology companies–major factor driving market growth 99
8.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM 101
8.5.3.1 Increasing applications of SSCP in virology are expected to play a key role in the growth of the SSCP market 101
8.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT (MALDI-TOF) MASS SPECTROMETRY 102
8.6.1 INCREASING APPLICATIONS OF THIS TECHNIQUE IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO DRIVE MARKET GROWTH 102
8.7 OTHER TECHNOLOGIES 104
9 GENOTYPING MARKET, BY APPLICATION 106
9.1 INTRODUCTION 107
9.2 PHARMACOGENOMICS 108
9.2.1 PHARMACOGENOMICS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GENOTYPING MARKET IN 2017 108
9.3 DIAGNOSTICS & PERSONALIZED MEDICINE 110
9.3.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING POTENTIAL OF DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TECHNIQUES ARE THE KEY FACTORS DRIVING THE GROWTH OF THIS APPLICATION SEGMENT 110
9.4 ANIMAL GENETICS 111
9.4.1 LOWER ADOPTION OF GENOTYPING TECHNOLOGIES IN ANIMAL BREEDING PROGRAMS IN DEVELOPING COUNTRIES TO RESTRAIN THE GROWTH OF THIS SEGMENT 111
9.5 AGRICULTURAL BIOTECHNOLOGY 113
9.5.1 INCREASING NUMBER OF RESEARCH LABORATORIES AND GREENHOUSES USING PLANT GENOTYPING AND CONTINUOUS PRODUCT INNOVATIONS AND NEW PRODUCT LAUNCHES ARE DRIVING THE GROWTH OF THE AGRICULTURAL BIOTECHNOLOGY SEGMENT 113
9.6 OTHER APPLICATIONS 114

10 GENOTYPING MARKET, BY END USER 116
10.1 INTRODUCTION 117
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 118
10.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 118
10.3 DIAGNOSTIC & RESEARCH LABORATORIES 119
10.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE AND INCREASING RESEARCH FOCUSED ON PERSONALIZED DIAGNOSIS ARE THE KEY FACTORS DRIVING MARKET GROWTH 119
10.4 ACADEMIC INSTITUTES 121
10.4.1 INCREASING RESEARCH ACTIVITIES FOR DRUG DISCOVERY AND RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT ARE THE KEY FACTORS DRIVING MARKET GROWTH 121
10.5 OTHER END USERS 122
11 GENOTYPING MARKET, BY REGION 124
11.1 INTRODUCTION 125
11.2 NORTH AMERICA 126
11.2.1 US 131
11.2.1.1 US dominated the North American genotyping market in 2018; this trend to continue during the forecast period 131
11.2.2 CANADA 135
11.2.2.1 Increasing incidence of genetic diseases & the availability of a wide range of genotyping products to drive market growth in Canada 135
11.3 EUROPE 139
11.3.1 GERMANY 144
11.3.1.1 Germany accounted for the largest share of the European genotyping market in 2017 144
11.3.2 FRANCE 148
11.3.2.1 Increasing incidence of genetic disorders & growing public-private investments are driving the growth of the genotyping market in France 148
11.3.3 UK 151
11.3.3.1 UK to witness the highest growth in the European genotyping market during the forecast period 151
11.3.4 ITALY 155
11.3.4.1 Presence of a well-developed healthcare system and rapid growth in the geriatric population are key factors driving market growth in Italy 155
11.3.5 SPAIN 159
11.3.5.1 The lingering effect of economic downturns will continue to affect healthcare in Spain 159
11.3.6 REST OF EUROPE 163
11.4 ASIA PACIFIC 166
11.4.1 CHINA 171
11.4.1.1 Infrastructural improvements in China’s healthcare system have boosted treatment rates and care delivery 171
11.4.2 JAPAN 175
11.4.2.1 Strong base of pharmaceutical activity will contribute to the use of genotyping 175
11.4.3 INDIA 179
11.4.3.1 Growth of the pharmaceutical industry has highlighted the need for better infrastructure in India 179
11.4.4 REST OF APAC 183
11.5 LATIN AMERICA 187
11.6 MIDDLE EAST AND AFRICA 191
12 COMPETITIVE LANDSCAPE 195
12.1 OVERVIEW 195
12.2 PRODUCT PORTFOLIO MATRIX 196
12.3 MARKET SHARE ANALYSIS 197
12.4 COMPETITIVE SITUATIONS AND TRENDS 198
12.4.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 200
12.4.2 ACQUISITIONS 201
12.4.3 EXPANSIONS 202
13 COMPANY PROFILES 204
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 ILLUMINA, INC. 204
13.2 THERMO FISHER SCIENTIFIC, INC. 210
13.3 ROCHE DIAGNOSTICS LIMITED 218
13.4 QIAGEN N.V. 223
13.5 DANAHER CORPORATION 230
13.6 AGILENT TECHNOLOGIES, INC. 233
13.7 FLUIDIGM CORPORATION 241
13.8 GE HEALTHCARE 244
13.9 GENEWIZ, INC. 248
13.10 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 251
13.11 PERKINELMER, INC. 255
13.12 BIO-RAD LABORATORIES, INC. 260
13.13 EUROFINS SCIENTIFIC 263
13.14 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 267

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14 APPENDIX 271
14.1 INSIGHTS OF INDUSTRY EXPERTS 271
14.2 DISCUSSION GUIDE 272
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
14.4 AVAILABLE CUSTOMIZATIONS 279
14.5 RELATED REPORT 279
14.6 AUTHOR DETAILS 280

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES 25
TABLE 2 GENOTYPING MARKET SNAPSHOT, 2018 VS. 2023 36
TABLE 3 COMPARATIVE DATA: OLDER VS LATEST PLATFORMS, BY COMPANY 49
TABLE 4 RECENT DEVELOPMENTS IN THE GENOTYPING MARKET 55
TABLE 5 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 60
TABLE 6 GENOTYPING MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 64
TABLE 7 GENOTYPING REAGENTS & KITS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 65
TABLE 8 GENOTYPING SERVICES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 66
TABLE 9 GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION) 68
TABLE 10 GENOTYPING INSTRUMENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 68
TABLE 11 GENOTYPING SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 69
TABLE 12 GENOTYPING ANALYZERS MARKET, BY COUNTRY, 2016–2023 ( USD MILLION) 71
TABLE 13 GENOTYPING BIOINFORMATICS MARKET, BY TYPE, 2016-2023, (USD MILLION) 72
TABLE 14 GENOTYPING BIOINFORMATICS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 73
TABLE 15 GENOTYPING BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 74
TABLE 16 GENOTYPING BIOINFORMATICS SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 75
TABLE 17 GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 77
TABLE 18 COMPARATIVE STUDY: REAL-TIME PCR VS DIGITAL PCR 78
TABLE 19 POLYMERASE CHAIN REACTION MARKET, BY TYPE, 2016–2023 (USD MILLION) 79
TABLE 20 POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 80
TABLE 21 MAJOR REAL-TIME PCR PRODUCTS AVAILABLE IN THE MARKET 81
TABLE 22 REAL-TIME PCR MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 82
TABLE 23 MAJOR DIGITAL PCR PRODUCTS AVAILABLE IN THE MARKET 83
TABLE 24 DIGITAL PCR MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 84
TABLE 25 MAJOR MICROARRAY PRODUCTS AVAILABLE IN THE MARKET 85
TABLE 26 MICROARRAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 87
TABLE 27 SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 89
TABLE 28 SEQUENCING MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 89
TABLE 29 MAJOR NEXT-GENERATION SEQUENCING PRODUCTS AVAILABLE IN THE MARKET 90
TABLE 30 NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 92
TABLE 31 MAJOR PYROSEQUENCING PRODUCTS AVAILABLE IN THE MARKET 93
TABLE 32 PYROSEQUENCING MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 94
TABLE 33 MAJOR SANGER SEQUENCING PRODUCTS AVAILABLE IN THE MARKET 95
TABLE 34 SANGER SEQUENCING MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 35 CAPILLARY ELECTROPHORESIS MARKET, BY TYPE, 2016–2023 (USD MILLION) 97
TABLE 36 CAPILLARY ELECTROPHORESIS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 97
TABLE 37 MAJOR AFLP PRODUCTS AVAILABLE IN THE MARKET 98
TABLE 38 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 99
TABLE 39 MAJOR RFLP PRODUCTS AVAILABLE IN THE MARKET 100
TABLE 40 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 100
TABLE 41 MAJOR SSCP PRODUCTS AVAILABLE IN THE MARKET 101
TABLE 42 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 101
TABLE 43 MAJOR MALDI-TOF PRODUCTS AVAILABLE IN THE MARKET 102
TABLE 44 MALDI-TOF MASS SPECTROMETRY MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 103
TABLE 45 MAJOR PRODUCTS AVAILABLE IN THE MARKET 104
TABLE 46 GENOTYPING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2016–2023 (USD MILLION) 105
TABLE 47 GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 107
TABLE 48 GENOTYPING MARKET FOR PHARMACOGENOMICS, BY COUNTRY,
2016–2023 (USD MILLION) 109
TABLE 49 GENOTYPING MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINE,
BY COUNTRY, 2016–2023 (USD MILLION) 111
TABLE 50 GENOTYPING MARKET FOR ANIMAL GENETICS, BY COUNTRY,
2016–2023 (USD MILLION) 112
TABLE 51 GENOTYPING MARKET FOR AGRICULTURAL BIOTECHNOLOGY,
BY COUNTRY, 2016–2023 (USD MILLION) 114
TABLE 52 GENOTYPING MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2016–2023 (USD MILLION) 115
TABLE 53 GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 117
TABLE 54 GENOTYPING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION) 119
TABLE 55 GENOTYPING MARKET FOR DIAGNOSTIC AND RESEARCH LABORATORIES,
BY COUNTRY, 2016–2023 (USD MILLION) 120
TABLE 56 GENOTYPING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,
2016–2023 (USD MILLION) 122
TABLE 57 GENOTYPING MARKET FOR OTHER END USERS, BY COUNTRY,
2016–2023 (USD MILLION) 123
TABLE 58 GENOTYPING MARKET, BY REGION, 2016–2023 (USD MILLION) 126
TABLE 59 NORTH AMERICA: GENOTYPING MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 128
TABLE 60 NORTH AMERICA: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 128
TABLE 61 NORTH AMERICA: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 128
TABLE 62 NORTH AMERICA: GENOTYPING BIOINFORMATICS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 63 NORTH AMERICA: GENOTYPING MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 129
TABLE 64 NORTH AMERICA: POLYMERASE CHAIN REACTION MARKET,
BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 65 NORTH AMERICA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 66 NORTH AMERICA: CAPILLARY ELECTROPHORESIS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 67 NORTH AMERICA: GENOTYPING MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 130
TABLE 68 NORTH AMERICA: GENOTYPING MARKET, BY END USER,
2016–2023 (USD MILLION) 131
TABLE 69 US: GENOTYPING MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 132
TABLE 70 US: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 132
TABLE 71 US: GENOTYPING BIOINFORMATICS MARKET, BY TYPE, 2016–2023 (USD MILLION) 132
TABLE 72 US: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 133
TABLE 73 US: POLYMERASE CHAIN REACTION MARKET, BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 74 US: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 75 US: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE, 2016–2023 (USD MILLION) 134
TABLE 76 US: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 134
TABLE 77 US: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 134
TABLE 78 CANADA: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 135
TABLE 79 CANADA: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 136
TABLE 80 CANADA: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 136
TABLE 81 CANADA: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 136
TABLE 82 CANADA: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 83 CANADA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 84 CANADA: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 85 CANADA: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 138
TABLE 86 CANADA: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 138
TABLE 87 EUROPE: GENOTYPING MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 141
TABLE 88 EUROPE: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 141
TABLE 89 EUROPE: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 141
TABLE 90 EUROPE: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 142
TABLE 91 EUROPE: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 142
TABLE 92 EUROPE: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 142
TABLE 93 EUROPE: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 143
TABLE 94 EUROPE: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 143
TABLE 95 EUROPE: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 143
TABLE 96 EUROPE: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 144
TABLE 97 GERMANY: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 145
TABLE 98 GERMANY: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 145
TABLE 99 GERMANY: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 145
TABLE 100 GERMANY: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 146
TABLE 101 GERMANY: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 146
TABLE 102 GERMANY: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 103 GERMANY: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 147
TABLE 104 GERMANY: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 147
TABLE 105 GERMANY: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 147
TABLE 106 FRANCE: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 148
TABLE 107 FRANCE: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 149
TABLE 108 FRANCE: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 149
TABLE 109 FRANCE: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 149
TABLE 110 FRANCE: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 150
TABLE 111 FRANCE: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 112 FRANCE: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 150
TABLE 113 FRANCE: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 151
TABLE 114 FRANCE: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 151
TABLE 115 UK: GENOTYPING MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 152
TABLE 116 UK: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 152
TABLE 117 UK: GENOTYPING BIOINFORMATICS MARKET, BY TYPE, 2016–2023 (USD MILLION) 153
TABLE 118 UK: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 153
TABLE 119 UK: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 154
TABLE 120 UK: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 154
TABLE 121 UK: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE, 2016–2023 (USD MILLION) 154
TABLE 122 UK: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 155
TABLE 123 UK: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 155
TABLE 124 ITALY: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 156
TABLE 125 ITALY: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 156
TABLE 126 ITALY: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 157
TABLE 127 ITALY: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 157
TABLE 128 ITALY: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 157
TABLE 129 ITALY: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 158
TABLE 130 ITALY: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 158
TABLE 131 ITALY: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 158
TABLE 132 ITALY: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 159
TABLE 133 SPAIN: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 160
TABLE 134 SPAIN: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 160
TABLE 135 SPAIN: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 160
TABLE 136 SPAIN: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 161
TABLE 137 SPAIN: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 161
TABLE 138 SPAIN: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 161
TABLE 139 SPAIN: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 162
TABLE 140 SPAIN: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 162
TABLE 141 SPAIN: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 162
TABLE 142 ROE: GENOTYPING MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 163
TABLE 143 ROE: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 144 ROE: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 164
TABLE 145 ROE: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 164
TABLE 146 ROE: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 164
TABLE 147 ROE: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 165
TABLE 148 ROE: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 165
TABLE 149 ROE: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 165
TABLE 150 ROE: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 166
TABLE 151 APAC: GENOTYPING MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 168
TABLE 152 APAC: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 168
TABLE 153 APAC: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 168
TABLE 154 APAC: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 155 APAC: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 169
TABLE 156 APAC: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 157 APAC: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 158 APAC: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 170
TABLE 159 APAC: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 170
TABLE 160 APAC: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 171
TABLE 161 CHINA: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 172
TABLE 162 CHINA: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 172
TABLE 163 CHINA: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 173
TABLE 164 CHINA: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 173
TABLE 165 CHINA: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 173
TABLE 166 CHINA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 174
TABLE 167 CHINA: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 174
TABLE 168 CHINA: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 174
TABLE 169 CHINA: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 175
TABLE 170 JAPAN: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 176
TABLE 171 JAPAN: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 176
TABLE 172 JAPAN: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 176
TABLE 173 JAPAN: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 177
TABLE 174 JAPAN: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 177
TABLE 175 JAPAN: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 177
TABLE 176 JAPAN: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 178
TABLE 177 JAPAN: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 178
TABLE 178 JAPAN: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 178
TABLE 179 INDIA: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 180
TABLE 180 INDIA: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 180
TABLE 181 INDIA: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 180
TABLE 182 INDIA: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 181
TABLE 183 INDIA: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 181
TABLE 184 INDIA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 181
TABLE 185 INDIA: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 182
TABLE 186 INDIA: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 182
TABLE 187 INDIA: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 182
TABLE 188 ROAPAC: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 183
TABLE 189 ROAPAC: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 184
TABLE 190 ROAPAC: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 184
TABLE 191 ROAPAC: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 184
TABLE 192 ROAPAC: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 185
TABLE 193 ROAPAC: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 185
TABLE 194 ROAPAC: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 185
TABLE 195 ROAPAC: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 186
TABLE 196 ROAPAC: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 186
TABLE 197 LATIN AMERICA: GENOTYPING MARKET, BY PRODUCT & SERVICE,
2016–2023 (USD MILLION) 187
TABLE 198 LATIN AMERICA: GENOTYPING INSTRUMENTS MARKET, BY TYPE,
2016–2023 (USD MILLION) 188
TABLE 199 LATIN AMERICA: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 188
TABLE 200 LATIN AMERICA: GENOTYPING MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 188
TABLE 201 LATIN AMERICA: POLYMERASE CHAIN REACTION MARKET,
BY TYPE, 2016–2023 (USD MILLION) 189
TABLE 202 LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 189
TABLE 203 LATIN AMERICA: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 189
TABLE 204 LATIN AMERICA: GENOTYPING MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 190
TABLE 205 LATIN AMERICA: GENOTYPING MARKET, BY END USER,
2016–2023 (USD MILLION) 190
TABLE 206 MEA: GENOTYPING MARKET, BY PRODUCT & SERVICE, 2016–2023 (USD MILLION) 191
TABLE 207 MEA: GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 192
TABLE 208 MEA: GENOTYPING BIOINFORMATICS MARKET, BY TYPE,
2016–2023 (USD MILLION) 192
TABLE 209 MEA: GENOTYPING MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 192
TABLE 210 MEA: POLYMERASE CHAIN REACTION MARKET, BY TYPE,
2016–2023 (USD MILLION) 193
TABLE 211 MEA: SEQUENCING MARKET, BY TYPE, 2016–2023 (USD MILLION) 193
TABLE 212 MEA: CAPILLARY ELECTROPHORESIS MARKET, BY TYPE,
2016–2023 (USD MILLION) 193
TABLE 213 MEA: GENOTYPING MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 194
TABLE 214 MEA: GENOTYPING MARKET, BY END USER, 2016–2023 (USD MILLION) 194
TABLE 215 GROWTH STRATEGY MATRIX (2015–2018) 196
TABLE 216 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, 2015–2018 199
TABLE 217 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2015–2018 200
TABLE 218 ACQUISITIONS, 2015–2018 201
TABLE 219 EXPANSIONS, 2015–2018 203


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 26
FIGURE 2 PRIMARY SOURCES 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 31
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):
BY END USER AND REGION 32
FIGURE 5 DATA TRIANGULATION METHODOLOGY 34
FIGURE 6 GENOTYPING MARKET, BY PRODUCT & SERVICE, 2018 VS. 2023 (USD MILLION) 37
FIGURE 7 GENOTYPING INSTRUMENTS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 38
FIGURE 8 BIOINFORMATICS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 38
FIGURE 9 GENOTYPING MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD MILLION) 39
FIGURE 10 PCR MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 39
FIGURE 11 SEQUENCING MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 40
FIGURE 12 CAPILLARY ELECTROPHORESIS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 41
FIGURE 13 GENOTYPING MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION) 41
FIGURE 14 GENOTYPING MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 42
FIGURE 15 GENOTYPING MARKET: GEOGRAPHICAL SNAPSHOT 43
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS AND DECREASING PRICES OF DNA SEQUENCING ARE DRIVING MARKET GROWTH 44
FIGURE 17 REAGENTS & KITS COMMANDED THE LARGEST SHARE OF THE MARKET IN 2017 45
FIGURE 18 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE GENOTYPING MARKET
IN 2017 46
FIGURE 19 ASIA PACIFIC TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 47
FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD 47
FIGURE 21 COMPARATIVE ANALYSIS OF HUMAN WHOLE-GENOME SEQUENCING COST
AND AMOUNT OF DATA PRODUCED PER GENOME (2001–2017) 50
FIGURE 22 FDA 510(K) APPROVAL PROCESS 57
FIGURE 23 EUROPE: CLASSIFICATION OF GENOTYPING PRODUCTS 58
FIGURE 24 REGULATORY PROCESS FOR GENOTYPING PRODUCTS IN JAPAN 59
FIGURE 25 INDIA: REGULATORY PROCESS FOR GENOTYPING PRODUCTS 60
FIGURE 26 REAGENTS & KITS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2018–2023) 64
FIGURE 27 SEQUENCERS & AMPLIFIERS SEGMENT TO REGISTER THE HIGHEST GROWTH
IN THE GENOTYPING INSTRUMENTS MARKET DURING THE FORECAST PERIOD 67
FIGURE 28 SOFTWARE SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE GENOTYPING BIOINFORMATICS MARKET DURING THE FORECAST PERIOD 72
FIGURE 29 SEQUENCING SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2018–2023) 77
FIGURE 30 REAL-TIME PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2023 79
FIGURE 31 NGS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 88
FIGURE 32 AFLP SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 96
FIGURE 33 PHARMACOGENOMICS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 107
FIGURE 34 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO WITNESS THE HIGHEST GROWTH RATE IN THE GENOTYPING MARKET DURING THE FORECAST PERIOD 117
FIGURE 35 GEOGRAPHICAL SNAPSHOT: MARKETS IN ASIA PACIFIC ARE EMERGING HOTSPOTS 125
FIGURE 36 NORTH AMERICA: GENOTYPING MARKET SNAPSHOT 127
FIGURE 37 EUROPE: GENOTYPING MARKET SNAPSHOT 140
FIGURE 38 APAC: GENOTYPING MARKET SNAPSHOT 167
FIGURE 39 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN
JANUARY 2015 AND MARCH 2018 195
FIGURE 40 GENOTYPING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 197
FIGURE 41 PRODUCT LAUNCHES, APPROVALS, & ENHANCEMENTS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2015 & 2018 198
FIGURE 42 ILLUMINA, INC.: COMPANY SNAPSHOT (2017) 204
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2017) 210
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2017) 218
FIGURE 45 QIAGEN N.V.: COMPANY SNAPSHOT (2017) 223
FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2017) 230
FIGURE 47 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2017) 233
FIGURE 48 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2017) 241
FIGURE 49 GE HEALTHCARE: COMPANY SNAPSHOT (2017) 244
FIGURE 50 PERKINELMER, INC.: COMPANY SNAPSHOT (2017) 255
FIGURE 51 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017) 260
FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2017) 263
FIGURE 53 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY SNAPSHOT (2017) 267


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ジェノタイピングアッセイの世界市場予測(~2023年)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆